Elsevier

International Journal of Cardiology

Volume 167, Issue 6, 10 September 2013, Pages 2875-2881
International Journal of Cardiology

Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients

https://doi.org/10.1016/j.ijcard.2012.07.021Get rights and content

Abstract

Background

Various human cardiovascular pathophysiological conditions associate aberrant expression of microRNAs (miRNAs) and circulating miRNAs are emerging as promising biomarkers. In mice, myocardial miR-21 overexpression is related to cardiac fibrosis elicited by pressure overload. This study was designed to determine the role of myocardial and plasmatic miR-21 in the maladaptive remodeling of the extracellular matrix induced by pressure overload in aortic stenosis (AS) patients and the clinical value of miR-21 as a biomarker for pathological myocardial fibrosis.

Methods

In left ventricular biopsies from 75 AS patients and 32 surgical controls, we quantified the myocardial transcript levels of miR-21, miR-21-targets and ECM- and TGF-β-signaling-related elements. miR-21 plasma levels were determined in 25 healthy volunteers and in AS patients. In situ hybridization of miR-21 was performed in myocardial sections.

Results

The myocardial and plasma levels of miR-21 were significantly higher in the AS patients compared with the controls and correlated directly with the echocardiographic mean transvalvular gradients. miR-21 overexpression was confined to interstitial cells and absent in cardiomyocytes. Using bootstrap validated multiple linear regression, the variance in myocardial collagen expression was predicted by myocardial miR-21 (70% of collagen variance) or plasma miR-21 (52% of collagen variance), together with the miR-21 targets RECK and PDCD4, and effectors of TGF-ß signaling.

Conclusions

Our results support the role of miR-21 as a regulator of the fibrotic process that occurs in response to pressure overload in AS patients and underscore the value of circulating miR-21 as a biomarker for myocardial fibrosis.

Introduction

Degenerative aortic stenosis (AS) has become the most frequent type of valvular disease in industrialized countries (2–7% of the population older than 65 years) and its incidence is rising in parallel to the increasing life expectancy [1]. Surgical aortic valve replacement is the only therapy with confirmed survival benefit, and at present, no medical therapy can delay the inevitability of surgery. Older age is associated with a higher frequency of comorbidity, which contributes to increased operative risk and renders decision-making for intervention more complex [2]. Under pathological pressure loading, such as AS, the left ventricle (LV) experiences a remodeling process that is characterized by the hypertrophic growth of cardiomyocytes and the increased deposition of extracellular matrix (ECM) elements [3]. The development of diffuse, reactive myocardial fibrosis is a major cause of abnormal myocardial stiffness [4] which results in systolic and/or diastolic dysfunction that is proportional to the degree of ECM deposition [5], [6], [7], [8]. The extent of myocardial fibrosis, which may not be reversible after delayed surgery, has important prognostic implications, because it is an independent predictor of perioperative mortality [9] and a key determinant of long-term functional outcome following aortic valve replacement [5], [10], [11].

MicroRNAs (miRNAs) are non-coding small RNAs that modulate the expression of target genes by repressing translation and/or inducing mRNA degradation. The aberrant expression of miRNAs is associated with multiple pathological processes, including processes that affect the cardiovascular system [12], [13], [14], [15]. To date, few studies have analyzed the differential expression profiling of miRNAs in failing human hearts of different etiologies in comparison with control patients [16], [17], [18]. The distinctive pattern of miRNA expression changes between heart diseases has led to the suggestion that miRNAs may have etiological implications and that their expression profiles could be useful as potential biomarkers for diagnosing patients and predicting the prognosis and response to therapy [19]. One particular miRNA that is consistently deregulated under various cardiovascular pathological conditions is miR-21 [20]. Through loss-of-function and gain-of-function approaches, a key regulatory role for miR-21 has been evidenced in the pathological remodeling of the myocardium induced by hemodynamic stress [21], [22], [23]. The up-regulation of miR-21 in response to cardiac injury protects fibroblasts against apoptosis, which results in LV interstitial fibrosis and hemodynamic dysfunction [22]. The relationship of miR-21 up-regulation with the remodeling of ECM has also been demonstrated in mouse models of ischemia/reperfusion and acute myocardial infarction [24], [25], [26]. miR-21 was postulated to repress the transcription of myocardial mRNA targets including sprouty homolog 1 (SPRY1) [22], phosphatase and tensin homolog (PTEN) [23] and programmed cell death 4 (PDCD4) [27], [28]. In addition, some miR-21 targets validated in extracardiac tissues [29], such as reversion-inducing-cysteine-rich protein with kazal motifs (RECK) and the tissue inhibitor of metalloproteinase 3 (TIMP3), play key roles in the control of the ECM homeostasis [30], [31] which deserve further attention in the scenario of human pressure overload.

Transforming growth factor-β1 (TGF-β1) is a crucial player in the LV remodeling response to hemodynamic stress [3] both in rodent models [32], [33] and in AS patients [5], [8], [34]. The involvement of miR-21 in the molecular mechanism underlying the effects of TGF-β1 has become a key focus of recent research. Smads, which are the canonical effectors of TGF-β signaling, regulate the transcription of primary miR-21 and its post-transcriptional processing by the DROSHA complex [35]. In TGF-β-dependent events, miR-21 is closely linked to the abnormal and excessive deposition of ECM [20], [36], and several reports determined that miR-21 acts downstream of TGF-β to modulate the genesis and progression of pathological fibrotic processes in the liver [37], kidneys [38], [39] and lungs [40]. Overall, these findings led us to hypothesize that miR-21 could be an actor in the pressure overload-induced ECM remodeling process dependent on TGF-β signaling in AS patients.

Recent reports indicate the presence of circulating miRNAs in microvesicles or protein–miRNA-complexes that can be consistently quantified in human plasma and other body fluids [41]. Several studies reported altered plasma levels of various miRNAs in cardiovascular diseases [42], including acute myocardial infarction, stable coronary artery disease, acute and chronic heart failure and myocarditis [43]. Therefore, the altered circulating levels of selected miRNAs may reflect specific cardiovascular pathologies and could be useful biomarkers for cardiovascular diseases. However, there are no data available on the possible function of circulating/extracellular miRNAs as endocrine/paracrine signaling molecules that contribute to cardiovascular disease pathogenesis.

Thus, the aim of this study was to investigate the following: (a) the role of both myocardial and plasmatic miR-21 in the maladaptive ECM remodeling induced by pressure overload in AS patients; (b) the association between validated miR-21 targets and TGF-β signaling effectors; and (c) the potential clinical value of miR-21 as a disease biomarker for pathological myocardial fibrosis progression.

Section snippets

Methods

The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology.

Results

The preoperative echocardiographic, clinical and demographic data of the patient cohorts are shown in Table 1. Patient demographic and clinical characteristics were presented as means ± standard deviation.

Discussion

Abundant evidence derived from basic research suggests a key role for several miRNAs, including miR-21, in the pathophysiology of many cardiovascular pathological processes. However, a direct assessment of their involvement in human heart diseases has rarely been addressed [19]. In the present study, which was performed in one of the largest series of intraoperative LV myocardial biopsies from AS patients, we provided evidence supporting a significant role for miR-21 in the pathological

Funding sources

This work was supported by the Instituto de Salud Carlos III [PI09/01097], Ministerio de Ciencia e Innovación (SAF2010-16894), Fundación Marqués de Valdecilla-Universidad de Cantabria [FMV-UC 09/01], and Instituto de Formación e Investigación Marqués de Valdecilla [FMV-API 10/20].

Acknowledgments

We thank Dr. Javier Llorca for statistical advice. We acknowledge the technical assistance of Amalia Cavayé, Ana Cayón, Nieves García, Elena Martín, RN, Roberto Moreta, RN and Ana Sandoval. The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology.

References (52)

  • Z. Kassiri et al.

    Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart

    J Biol Chem

    (2009)
  • R.T. Marquez et al.

    Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans

    Lab Invest

    (2010)
  • E.M. Kroh et al.

    Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR)

    Methods

    (2010)
  • S. Jørgensen et al.

    Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes

    Methods

    (2010)
  • B.N. Davis et al.

    Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha

    Mol Cell

    (2010)
  • M. Tatsuguchi et al.

    Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy

    J Mol Cell Cardiol

    (2007)
  • A Vahanian et al.

    Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European Society of Cardiology

    Eur Heart J

    (2007)
  • K. Yamamoto et al.

    Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart

    Cardiovasc Res

    (2002)
  • W.M. Yarbrough et al.

    Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications

    J Thorac Cardiovasc Surg

    (2011)
  • S. Heymans et al.

    Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart

    Circulation

    (2005)
  • L.H. Lund et al.

    Myocardial structure as a determinant of pre- and postoperative ventricular function and long-term prognosis after valve replacement for aortic stenosis

    Eur Heart J

    (1998)
  • F. Weidemann et al.

    Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis

    Circulation

    (2009)
  • E.M. Small et al.

    MicroRNAs add a new dimension to cardiovascular disease

    Circulation

    (2010)
  • A.J. Tijsen et al.

    Non-cardiomyocyte microRNAs in heart failure

    Cardiovasc Res

    (2011)
  • A.V. Villar et al.

    Myocardial gene expression of microRNA-133a and myosin heavy and light chains, in conjunction with clinical parameters, predict regression of left ventricular hypertrophy after valve replacement in patients with aortic stenosis

    Heart

    (2011)
  • E. van Rooij et al.

    A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure

    Proc Natl Acad Sci U S A

    (2006)
  • Cited by (117)

    • Circulating MicroRNAs as Biomarkers and Diagnosis Tool for Diseases

      2023, MicroRNA in Regenerative Medicine, Second Edition
    • Advances in congestive heart failure biomarkers

      2023, Advances in Clinical Chemistry
    View all citing articles on Scopus
    1

    The first two authors contributed equally to this work.

    2

    MAH and JFN contributed equally to the design and direction of this work and both are corresponding authors.

    View full text